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A B S T R A C T
Stromal cells, deriving from mesenchymal stromal cells (MSCs), are crucial component of tumour microenvironment and represent key regulators of tumour pro-
cesses. MSCs can be recruited to the tumour environment and interact with many cellular elements, thus influencing tumour biology. Cell-to-cell communication is in
part mediated by the release of extracellular vesicle (EVs). EVs can induce significant molecular changes in recipient cells, delivering bioactive molecules. In this
review, we describe the MSC-derived EVs content and discuss their role in different processes related to cancer biology. Furthermore, we summarize chemical or
biological EVs modifications aiming to develop more efficient antitumor therapies.
1. Introduction
Tumour initiation and progression require the generation of a sup-
portive niche that constitute a favourable microenvironment promoting
tumour cell viability, proliferation, and invasion. Different cell types
contribute to the tumour cell niche including stromal cells, endothelial
cells and immune cells. Stromal cells represent the main cell component
with both supportive and immunoregulatory functions; they derived
from multipotent cells of mesodermal origin, called mesenchymal
stromal cells (MSCs), which virtually reside in all tissues [1]. Therefore,
stromal cells can be recruited to the tumour environment and establish
dynamic interactions with tumour cells and other cellular elements
[2–4]. The role of MSCs in tumour microenvironment has been in-
creasingly studied in the last years. MSCs have shown to enhance or
suppress tumour progression and metastasis both in vitro and in vivo
depending not only on tumour model and stage considered, but also on
the dose and time of cell treatment [5,6].
Recently, a new mechanism of intercellular communication within
the tumour microenvironment has been recognized. This mechanism
involves the release of membrane-derived vesicles, called extracellular
vesicles (EVs). EVs include exosomes, the smallest EV fraction arising
from intracellular endosomes, and microvesicles (MVs) that are gen-
erated by budding from the plasma membrane. EVs influence various
biological processes by both activating directly into target cell surface
receptors through protein and bioactive lipid ligands, and delivering
different effectors, including transcription factors, oncogenes, mRNAs,
and non-coding regulatory RNAs (lncRNAs), thus inducing functional
changes in recipient cells [7]. The pattern of proteins, lipids, and nu-
cleic acids contained in EVs depends on their cell origin and may be
influenced by different environmental conditions. EVs are released by
either tumour cells or their surrounding cells and are considered as
important mediators of the cell cross-talk in the tumour micro-
environment. Tumour-derived EVs are involved in the immune re-
sponse regulation, thus creating an immunosuppressive niche and
triggering immune escape mechanisms [8]. Furthermore, tumour-de-
rived EVs contribute to the formation of metastasis by inducing per-
sistent molecular changes in stromal components, promoting angio-
genesis and epithelial–mesenchymal transition (EMT) [8]. On the other
hand, EVs derived from MSCs (MSC-EVs) can regulate cell apoptosis,
proliferation, invasion of tumour cells and influence several tumour
processes by delivering their content in recipient cells (Fig. 1). Although
the role of tumour-EVs is rather well-defined, MSC-EVs, as the origi-
nating cells, can act on tumour progression with opposite effect and
their role has not been clearly elucidated yet. In this review, we report
recent findings on the role of MSC-EVs in tumour biology, focusing on
their involvement in tumour growth, angiogenesis and drug resistance
(Table 1).
2. MSC-derived extracellular vesicles: characterization and
composition
Considering the different mechanisms of biogenesis, the composi-
tion in surface molecules of exosomes and MVs is quite different.
Exosomes derived from MSCs express the well-established exosome
markers CD63, CD9, CD81, Alix, LAMP1, HSP70 [9]. The expression of
typical MSC markers, such as CD29, CD73, CD90, CD44 and CD105, has
been further reported [10]. Membrane lipid composition of MSC-EVs is
enriched with diacylglycerol, sphingomyelin, and ceramides; in
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addition to their structural role, these lipids have a broad effect on
signal transduction and regulation known tumour suppressor, po-
tentiating signalling pathways that drive apoptosis and cell cycle arrest
[11,12]. On the other hand, alterations in ceramide turnover favour the
opposite effect promoting cell growth [13]. Furthermore, cancer cells
are associated to low level of sphingomyelin. The specific activation of
sphingomyelin synthases has been shown to lead to cell cycle arrest,
cell differentiation and apoptosis in cancer cells [14]. Diacylglycerol
kinases, a family of enzymes catalysing the transformation of dia-
cylglycerol into phosphatidic acid, are often up-regulated in many tu-
mour cell types, suggesting that the reduction of diacylglycerol could
promote tumour immune-escape [15]. Taken together, these data open
an important scenario on the role of lipid transfer mediated by MSC-EVs
on tumour processes. Moreover, MSC-EVs contain various bioactive
factors that could be involved in several pro or anti-tumour processes,
including transcription factors, oncogenes, and nucleic acids, such as
mRNAs and small and lncRNAs. MSC-EVs content could be strictly af-
fected by the tissue of origin. Through high-throughput techniques,
Vallabhaneni et al. described several known tumour supportive factors
in bone marrow-MSC-EVs (BM-MSC-EVs), such as PDGFR-beta, TIMP-1,
and TIMP-2 [11]. BM-MSC-EVs showed also the expression of miRNA-
21 and miRNA-34a that are involved in cell survival and proliferation
[11,16]. MVs released by human umbilical cord-derived MSCs (UC-
MSCs) have shown to express many angiogenesis-promoting molecules,
including IL-6, bFGF, and UPAR. MSC-MVs also contain angiogenin,
VEGF, MCP-1 and the receptor-2 for vascular endothelial growth factor
[17]. Furthermore, under hypoxic condition, the expression of some of
these cytokines are higher than under normoxic condition [17]. Re-
cently, several works explored the protein expression profile of exo-
some or MV-enriched fraction derived from MSCs, thus identifying a
wide spectrum of proteins associated to inflammation, Wnt signalling
pathway components and several putative paracrine effectors of an-
giogenesis [18,19]. Among the molecules contained in MSC-EVs, many
functionally active mRNAs and non-coding RNAs involved in the cross-
talk between tumour cells and MSCs have been described [20]. Iden-
tified miRNAs can be classified in families or clusters with different
functions. Let-7 and miR-15-16 families released by MSC-EVs mainly
possess anti-tumour activity, targeting oncogenes such as RAS, MYC,
HMAGA2, and LIN28, and the angiogenic factor VEGF-A, respectively
[21]. MiR-221 and miR-222 are also involved in angiogenic mechan-
isms and they have been identified in EVs released by rat MSCs [22].
The expression of lncRNAs has been increasingly studied in human
cancer cells and more recently in EVs. In human BM-MSC-EVs the ex-
pression of lncRNA involved in cell proliferation, such as lnc-7SK, has
been found, thus suggesting their possible role in tumour regulation
[11].
Fig. 1. Bioactive molecules contained in MSC-EVs. Circles represent bioactive molecules contained in MSC-EVs and potentially transferred in tumour cells and/or
other cell elements belonging to the tumour microenvironment. These molecules can modulate different genes and pathways in recipient cells, thus influencing
tumour cell survival and growth (green), angiogenesis (red) and drug resistance (light blue). Purple circles represent bioactive molecules loaded in EVs to develop EV-
based drugs.
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3. MSC-EVs as regulators of tumour cell survival and growth
The role of MSC-EVs during tumour growth has not been clearly
elucidated yet. To date, contradictory results have been reported. Some
authors have reported a supportive effect toward tumour cells in vitro
and in vivo, while other studies have demonstrated the opposite effect.
Recently, Dong et al [23]. showed in vivo a pro-tumour activity of EVs
derived from UC-MSCs on lung adenocarcinoma (LUAD) growth; in
fact, proliferation and apoptosis of LUAD cells were supported by the
EV-mediated transfer to cancer cells of miR-410 that directly targets
PTEN. MVs released by human Wharton's Jelly MSCs (WJ-MSCs) dis-
played the same supportive activity on renal cancer cell growth and
diffusion both in vitro and in vivo, promoting the progression of cell
cycle from G0/1 to S in tumour cells [24]. In this system, the MSC-MV-
mediated transfer of RNA induced HGF synthesis in tumour cells, thus
activating AKT and ERK1/2 signalling. The involvement of ERK1/2
signalling was also previously reported by Zhu et al., who showed the
activation of such pathway in a human cancer cell line (SGC-7901)
treated with MSC-exosomes [25]. Moreover, tumour incidence in mice
implanted with SGC-7901 cells or a human colon cancer cell line
(SW480) mixed with BM-MSCs or MSC-exosomes was similar and sig-
nificantly higher than in mice implanted with tumour cells alone [25].
On the other hand, the inhibitory effect of MSC-EVs on tumour growth
has been suggested by various reports. MSC-EVs reduced cell cycle
progression in HepG2 hepatoma, Kaposi's sarcoma, and Skov-3 ovarian
tumour cell lines, while they induced apoptosis in HepG2 and Kaposi's
cells and necrosis in Skov-3 [26]. Furthermore, BM-MSC-exosomes
promoted dormancy in metastatic breast cancer cells [27]. Such effect
has been correlated to the down-regulation of MARCKS expression in
cancer cells mediated by the EV-transfer of miR-23b. Human WJ-MSC-
EVs induced cell cycle arrest and apoptosis on bladder tumour T24 cells
in vitro and in vivo, through the reduction of phosphorylated AKT pro-
tein kinase and the increase of cleaved caspase-3 [28]. Moreover,
exosomes secreted by human Adipose Tissue-derived MSCs (AT-MSCs)
reduced cell viability, wound-repair capacity, and colony formation
ability of A2780 and Skov3 ovarian cancer cells [29]. In particular,
A2780 cells responded dose- and time-dependently following AT-MSC-
exosomes treatment and they showed a strong upregulation of several
pro-apoptotic signalling molecules, including phosphorylated p53,
BAX, activated Caspase9, and activated Caspase3, in association with a
down regulation of the anti-apoptotic BCL2 protein [29]. The con-
troversial data on the effect of MSC-EVs on tumour growth highlight the
complexity of their functions, that could be even opposite depending on
several factors, such as the type and the tissue origin of MSCs; in ad-
dition, cancer cells may show different responses depending on the
tumour model considered. The results can be also influenced by the
method of EV isolation: some authors purified exosomes or MV-en-
riched fraction, while others did not purify the two classes of EVs.
Moreover, the method of MSC culture may affect the experimental re-
sults. Serum-deprivation, a cell culture system often used for EVs iso-
lation, can modify the expression of important molecules involved in
cell survival and apoptosis, such as miR-21 and miR34a, which in turn
can affect the release and content of EVs [11]. In the context of multiple
myeloma, opposite effects of MSC-exosomes derived from either normal
individuals or patients were observed on tumour cell growth. MSC-EVs
derived from patients induced tumour growth, whereas MSC-EVs de-
rived from healthy donor showed an anti-tumour effect [30]. Further-
more, the role of MSC-EVs could be different according to the patho-
logical stage of the tumour. Vallabhaneni et al. showed that MSC-EVs
supported primary breast tumour progression, but reduced metastasis
formation through the UBE2N/Ubc13 pathway [31]. Therefore, tumour
model and stage as well as MSC culture conditions are all factors that
may influence the release of EVs, their content, and therefore their
effects on tumour growth.
3.1. MSC-EVs and angiogenesis
The influence of EVs released by various cell types on vascular de-
velopment, growth, and maturation has been widely documented and
reviewed by Todorova et al. [32]. The role of EVs on angiogenesis has
been assessed on both endothelial cells, evaluating their effect in
modulating vascular structures, and tumour cells, studying the ex-
pression of pro- and anti-angiogenic factors [33].
Angiogenesis plays a crucial role in numerous physiological and
pathological responses. Tumour development requires blood vessels for
oxygen and nutrients supply, which are both essential factors for tu-
mour growth. Tumour cells frequently overexpress pro-angiogenic
factors, such as VEGF, strictly associated with cancer progression [34].
MSCs contribute to this process by controlling blood vessel density and
functions [35]. As already underlined for tumour cell survival and
growth, the effect of MSCs on angiogenesis have yielded contradictory
results, including both anti-angiogenic and pro-angiogenic effects
[36,37]. Although the evidence of strong pro-angiogenic properties
correlated with the secretion of soluble factors and EVs by tumour
components, the effect of MSC-EVs on tumour angiogenesis remains
relatively unclear [32]. Murine MSC-EVs may shuttle anti-angiogenic
molecules into tumour cells, such as miR-16, a miRNA known to target
VEGF, leading to the inhibition of angiogenesis both in vitro and in vivo
models of breast cancer [38]. On the contrary, Zhu et al. clearly de-
monstrated that BM-MSC-exosomes strongly increase in vitro the ex-
pression of CXCR4 and VEGF in human gastric carcinoma (SGC-7901)
and colon cancer (SW480) cell lines [25]. These authors observed that
MAPK pathway, including ERK1/2 and p38, and - in minimal part - JNK
pathway, were responsible for the increase of VEGF and CXCR4 after
MSC-exosomes treatment. Furthermore, MSC-exosomes strongly induce
the expression of α-SMA, CXCR4, VEGF and MDM2 in in vivo [25]. In
breast cancer cells, BM-MSC-derived exosomes may induce a significant
reduction of VEGF expression and secretion by modulating the mTOR/
HIF-1α signalling axis and affecting the vascular behaviour of en-
dothelial cells in vitro [39]. In addition, VEGF down-regulation has been
associated with the horizontal transfer of miR-100 mediated by MSC-
exosomes, which has been further confirmed by the ability of anti-miR-
100 to rescue the inhibitory effects of MSC-derived exosomes [39].
Liang et al. showed the opposite effect mediated by exosomes secreted
by human Adipose Tissue-derived MSCs (AT-MSCs) [33]. In this ex-
perimental model, MSC-exosomes promoted angiogenic processes in
vitro by inducing the upregulation of the pro-angiogenic genes Ang1
(ANGPT1) and Flk1 (KDR) and the downregulation of the anti-angio-
genic factors Vash1 and TSP1 in endothelial cells (HUVECs) [33]. MSC-
exosomes may also increase the number of vascular structures in vivo.
These observations correlated with the transfer of miR-125, mediated
by MSC-exosomes, targeting the angiogenic inhibitor delta-like 4
(DLL4) [33]. Many other reports show that MSC-EVs contain various
miRNAs probably involved in modulating angiogenesis, including miR-
30b, miR-222, miR-21 and let-7f, and miR148a [40,41]. Furthermore,
McBride et al. showed the reduced ability of BM-MSC conditioned
medium to promote angiogenesis after CD63+ exosome depletion [42].
The pro-angiogenic activity was also shown in exosomes isolated from
UC-MSCs, with a mechanism dependent on Wnt4/β-catenin [43]. In
response to hypoxia, EVs isolated from AT-MSCs stimulated angiogen-
esis in vivo [44]. The ability of MSC-EVs to modulate angiogenic pro-
cesses was assessed in other contexts different from tumours. Con-
sidering their pro-angiogenic properties, MSC-EVs have been proposed
as novel therapeutic approaches for cardiovascular diseases as well as
brain, renal, and retinal injuries [45].
3.2. MSC-EVs and drug resistance
Drug resistance of cancer cells is a multifactorial process due to
dynamic interactions between tumour cells and the surrounding mi-
croenvironment. This process includes many mechanisms, such as
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defective drug accumulation, alteration of drug targets and cellular
pathways and, eventually, lack of induction of tumour cell death [46].
Tumour drug resistance mediated by microenvironmental stimuli has
been clearly underlined by several reports and reviewed in the context
of different tumours [47]. Tumour-EVs can mediated drug resistance
through several mechanisms, including drug sequestration, delivery of
specific RNA molecules and proteins, or through the well-known cross-
talk between cancer cells and MSCs [48]. MSC-exosomes containing
miR-222 and miR-223 may promote quiescence and drug resistance in
breast cancer cells [49]. Furthermore, Ono et al. demonstrated that BM-
MSC-exosomes decreased the sensitivity of breast cancer cells to doc-
etaxel [27]. UC-MSC-exosomes significantly induced drug resistance of
gastric cancer cells both in vivo and ex vivo [50]. MSC-exosomes in-
hibited 5-fluorouracil-induced apoptosis and promoted the expression
of various multi-drug resistance-associated proteins, such as MDR, MRP
and LRP. These findings have been associated to the activation of the
CaM-Ks/Raf/MEK/ERK pathway mediated by MSC-exosomes [50].
Furthermore, MSC-EVs may induce drug resistance also in haematolo-
gical tumours. BM-MSC-exosomes conferred resistance to bortezomib in
multiple myeloma cells by influencing several pathways, including p38,
p53, c-Jun N-terminal kinase, and Akt pathways [51]. BM-MSC-EVs
also increased the chemoresistance to several drugs commonly used for
chronic lymphocytic leukemia (CLL) B-cells, including fludarabine,
ibrutinib, idelalisib and venetoclax [52]. The treatment with MSC-EVs
significantly reduced the number of apoptotic CLL B-cells only after
24 h. Notably, EVs completely suppressed apoptosis induced by cla-
dribine and bortezomib [52]. In addition, rat MSC-EVs may protect rat
pheochromocytoma cells from the cytotoxicity induced by glutamate,
which induce the reduction of Bcl-2 expression with the concomitant
increase of Bax and cleaved caspase-3 expression. This effect was sig-
nificantly reversed by the pretreatment with MSC-MVs, suggesting their
protective effect in pheochromocytoma cells [53].
4. MSC-EVs and drug delivery
Pharmaceutical research has recently focused some strategies to
design drug carriers that could be used for delivering drugs specifically
to the site of interest [54]. Liposomes are considered an effective drug
delivery system based on nanotechnology science and may have nu-
merous therapeutic applications [55,56]. To date, at least 19 ther-
apeutic approaches with liposomal drug delivery systems have been
approved by FDA and EMA (www.fda.gov; www.ema.europa.eu/ema/
), and many phases I–III open interventional studies are in progress.
However, these formulations show several drawbacks related to stabi-
lity, fatty acyl moiety oxidation, drug loading, liposome targeting, and
drug leakage and release [57]. Considering the similarity between li-
posomes and EVs, the strategy to develop EV-based drugs has been
recently proposed. Compared to liposomes, EVs possess some ad-
vantages in terms of clearance and immunogenicity. In addition, EV
membranes are structurally comparable to cell membranes, thus fa-
vouring their biocompatibility and a lower toxicity [57]. Because of
their ability to deliver bioactive factors among cells, one of the most
intriguing therapeutic potential of EVs is the possibility to load them
with the desired drug. EVs can be theoretically loaded with both hy-
drophilic and lipophilic drugs and, interestingly, they can deliver them
to specific tissues, including the brain, considering their capacity to
cross the blood-brain barrier, where they have a high stability [58].
Experimentally, there are two different approaches for EV drug loading;
i.e. exogenously or endogenously. Endogenous loading can be carried
out by strong overexpression of the drug molecule in releasing cells,
while exogenous loading requires the collection of extracellular vesicles
before their loading with the desired drug by using different manip-
ulation, such as electroporation [45]. Pascucci et al. successfully ob-
tained MSC-EVs loaded with Paclitaxel, showing their in vitro efficacy
against pancreatic cancer cell growth [59]. Additionally, Del Fattore
et al. demonstrated that MSC-EV loading with Vincristine promoted
cytotoxicity toward glioblastoma cells, with a higher effect as compared
to both the free drug and the unloaded EVs [60]. The possibility to
directly engineer MSCs to secrete EVs enriched of specific components
with anti-tumour activity is emerging. Lou et al. reported encouraging
results in the context of hepatocellular carcinoma. Here, AT-MSCs were
transfected with a miR-122 expression plasmid, leading to the release of
miR-122 enriched exosomes. Such exosomes have shown to increase the
chemosensitovity of hepatocellular carcinoma cells in vitro by enhan-
cing cell apoptosis and cell cycle arrest, especially when HepG2 cell line
was considered [61]. Moreover, intra-tumour injection of miR-122
enriched exosomes sensitized hepatocellular carcinoma cells to sor-
afenib in vivo [61]. Considering that breast cancer cell lines stably ex-
pressing miR-379 showed a reduced capability in terms of tumour
formation and growth, O'Brien et al. proposed MSC-EVs enriched with
miR-397 as an innovative therapy for metastatic breast cancer [62].
They have engineered human BM-MSCs through lentiviral transduction
to release EVs enriched with miR-379 for in vivo therapeutic approach.
The treatment with cell-free EVs loaded with miR-379 had a therapeutic
effect with no adverse effects, while the administration of MSC ex-
pressing miR-397 did not interfere with tumour growth [57]. The same
experimental approach was previously reported by Yuan et al. using the
pro-apoptotic TNF-related apoptosis-inducing ligand (TRAIL) [63].
TRAIL and its receptors were used as targets of several anti-cancer
drugs, but the clinical application of recombinant TRAIL showed sev-
eral difficulties in terms of bioavailability and resistance of cancer cells.
These problems could be fixed by using MSC-EVs as TRAIL vehicle.
Yuan et al. developed TRAIL-enriched MSC-EVs and assessed their
cancer cell-killing efficacy [63]. TRAIL enriched MSC-EVs induced
apoptosis in 11 cancer cell lines in a dose-dependent fashion. They also
demonstrated that caspase activity inhibition or TRAIL neutralisation
abolished the cytotoxicity mediated by TRAIL-enriched EVs. Further-
more, the combined treatment of TRAIL-enriched MSC-EVs and CDK9
inhibitor enhanced the induction of apoptosis in TRAIL-resistant cancer
cells [63]. Despite these encouraging results, further pre-clinical studies
are necessary to clinically harness MSC-EVs as drug vehicle in the
context of tumours. Moreover, their therapeutic application is still
hampered by the lack of standardized and reproducible isolation and
drug loading methods. In addition, understanding which population of
EVs is most suitable for delivering drug molecules is also required for
future therapeutic approaches.
5. Conclusions
The bidirectional transfer of molecules between tumour cells and
tumour microenvironment plays a crucial role in cancer development.
In this context, MSC-EVs represent potential vehicles for the delivery of
pro- or anti-tumorigenic molecules. By transferring their content into
recipient cells, MSC-EVs significantly influence cancer cell survival,
growth, angiogenesis and drug resistance, even though some results are
still controversial because of the lack of conformity in the assessment of
biological functions. We discussed such controversial data specifying
relevant experimental information, including the effect mediated by
MVs or exosomes and MSC tissue sources. Nevetheless, standardized
protocols for isolation, quantification and characterization of EVs are
still required to clarify their role in tumour microenvironment and to
aim for potential clinical applications. Furthermore, because of the
capacity of EVs to encapsulate molecules, including proteins and nu-
cleic acids, therapeutic strategies based on engineered EVs are currently
on study and the preliminary results are quite promising, thus sup-
porting encouraging prospects for cancer treatment.
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